323 related articles for article (PubMed ID: 12454111)
1. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
[TBL] [Abstract][Full Text] [Related]
2. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
[TBL] [Abstract][Full Text] [Related]
5. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
DiFronzo LA; Gupta RK; Essner R; Foshag LJ; O'Day SJ; Wanek LA; Stern SL; Morton DL
J Clin Oncol; 2002 Aug; 20(15):3242-8. PubMed ID: 12149297
[TBL] [Abstract][Full Text] [Related]
6. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Morton DL; Hsueh EC; Essner R; Foshag LJ; O'Day SJ; Bilchik A; Gupta RK; Hoon DS; Ravindranath M; Nizze JA; Gammon G; Wanek LA; Wang HJ; Elashoff RM
Ann Surg; 2002 Oct; 236(4):438-48; discussion 448-9. PubMed ID: 12368672
[TBL] [Abstract][Full Text] [Related]
7. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
Hsueh EC; Gupta RK; Qi K; Morton DL
J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558
[TBL] [Abstract][Full Text] [Related]
8. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Sosman JA; Unger JM; Liu PY; Flaherty LE; Park MS; Kempf RA; Thompson JA; Terasaki PI; Sondak VK;
J Clin Oncol; 2002 Apr; 20(8):2067-75. PubMed ID: 11956267
[TBL] [Abstract][Full Text] [Related]
10. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
Hsueh EC; Morton DL
Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.
Hersey P; Coates AS; McCarthy WH; Thompson JF; Sillar RW; McLeod R; Gill PG; Coventry BJ; McMullen A; Dillon H; Simes RJ
J Clin Oncol; 2002 Oct; 20(20):4181-90. PubMed ID: 12377961
[TBL] [Abstract][Full Text] [Related]
12. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma.
Hsueh EC; Essner R; Foshag LJ; Ye W; Morton DL
Ann Surg Oncol; 2002 Jun; 9(5):486-92. PubMed ID: 12052761
[TBL] [Abstract][Full Text] [Related]
13. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer.
Habal N; Gupta RK; Bilchik AJ; Yee R; Leopoldo Z; Ye W; Elashoff RM; Morton DL
Ann Surg Oncol; 2001 Jun; 8(5):389-401. PubMed ID: 11407512
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.
Carson WE; Unger JM; Sosman JA; Flaherty LE; Tuthill RJ; Porter MJ; Thompson JA; Kempf RA; Othus M; Ribas A; Sondak VK
Cancer Immunol Res; 2014 Oct; 2(10):981-7. PubMed ID: 24994597
[TBL] [Abstract][Full Text] [Related]
15. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
Faries MB; Mozzillo N; Kashani-Sabet M; Thompson JF; Kelley MC; DeConti RC; Lee JE; Huth JF; Wagner J; Dalgleish A; Pertschuk D; Nardo C; Stern S; Elashoff R; Gammon G; Morton DL;
Ann Surg Oncol; 2017 Dec; 24(13):3991-4000. PubMed ID: 29019177
[TBL] [Abstract][Full Text] [Related]
17. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
[TBL] [Abstract][Full Text] [Related]
19. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
Dillman RO; McClay EF; Barth NM; Amatruda TT; Schwartzberg LS; Mahdavi K; de Leon C; Ellis RE; DePriest C
Cancer Biother Radiopharm; 2015 Jun; 30(5):187-94. PubMed ID: 26083950
[TBL] [Abstract][Full Text] [Related]
20. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
